In case you missed it: July 5 to July 9


It was a very busy week for the Contemporary OB/GYN® team.

This week’s top articles included:

Surprise bills for childbirth

In addition to welcoming a newborn, parents may be unexpectedly billed for some hospitalization services, according to a research letter in JAMA Health Forum.

Novel antifungal treatment approved for vaginal candidiasis

On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.

Visual Summary: Intrahepatic Cholestasis of Pregnancy

Refer to this visual summary from SMFM wherever you practice.

Meet the Board: Yalda Afshar, MD, PhD

Introducing Contemporary OB/GYN® Editorial Advisory Board member Yalda Afshar, MD, PhD.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit:
Unlocking the benefits of DHEA | Image Credit:
Unlocking the power of oxytocin | Image credit:
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit:
Deciding the best treatment for uterine fibroids | Image Credit:
Clinical pearls of pediatric dermatology | Image Credit:
Approaching inflammatory vulvovaginal diseases | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.